FIELD: medicine.
SUBSTANCE: declared group of inventions is a pharmaceutical composition for treating neurogenic or idiopathic bladder dysfunction, containing a therapeutically effective amount of a substance obtained from clostridia, and at least one permeabilising agent, wherein the substance obtained from clostridia is a botulinum toxin, and wherein at least one permeabilising agent contains a nonionic surfactant and a mucoadhesive substance, which is a cationic polymer, and wherein at least one permeabilising agent is present in an amount effective for substantial and reversible increase in the bladder wall permeability for the substance, obtained from clostridia and a method of treating a patient with neurogenic bladder dysfunction, comprising: an intravesical instillation on a bladder wall of a patient of the declared pharmaceutical composition.
EFFECT: declared group of inventions is highly effective for treating neurogenic or idiopathic bladder dysfunction.
17 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUPPRESSION OF ALLODYNIA INDUCED BY BONE CANCER | 2019 |
|
RU2791640C2 |
| IMPROVED BLADDER INJECTION SCHEME FOR ADMINISTRATION OF BOTULINUM TOXINS | 2017 |
|
RU2741966C2 |
| THERAPEUTIC FUSION PROTEINS | 2012 |
|
RU2651492C2 |
| STABILIZED NON-PROTEIN COMPOSITIONS OF CLOSTRIDIAL TOXIN | 2017 |
|
RU2762607C2 |
| LIQUID COMPOSITION OF NEUROTOXIN STABILIZED WITH TRYPTOPHAN OR TYROSINE | 2017 |
|
RU2741497C2 |
| CLOSTRIDIAL NEUROTOXINS WITH MODIFIED PERSISTENCE | 2009 |
|
RU2524429C2 |
| CATIONIC NEUROTOXINS | 2015 |
|
RU2733493C2 |
| NEUROTOXINS THAT DISPLAY REDUCED BIOLOGICAL ACTIVITY | 2010 |
|
RU2582266C2 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| PHARMACEUTICAL COMPOSITIONS OF CLOSTRIDIA TOXIN | 2009 |
|
RU2535003C2 |
